Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Cisplatin in Adjuvant NSCLC Stage I-II
NCT00293085Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Dec 2001
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of docetaxel and Cisplatin micelle injection (HA132) in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Central European Cooperative Oncology Group. Primary endpoint: Disease Free Survival. Started Dec 2001; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00293085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293085.